Human Immunodeficiency Virus Type 1 Vif Inhibits Packaging and Antiviral Activity of a Degradation-Resistant APOBEC3G Variant
- 1 August 2007
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (15) , 8236-8246
- https://doi.org/10.1128/jvi.02694-06
Abstract
Human immunodeficiency virus type 1 (HIV-1) Vif counteracts the antiviral activity of the human cytidine deaminase APOBEC3G (APO3G) by inhibiting its incorporation into virions. This has been attributed to the Vif-induced degradation of APO3G by cytoplasmic proteasomes. We recently demonstrated that although APO3G has a natural tendency to form RNA-dependent homo-multimers, multimerization was not essential for encapsidation into HIV-1 virions or antiviral activity. We now demonstrate that a multimerization-defective APO3G variant (APO3G C97A) is able to assemble into RNase-sensitive high-molecular-mass (HMM) complexes, suggesting that homo-multimerization of APO3G and assembly into HMM complexes are unrelated RNA-dependent processes. Interestingly, APO3G C97A was highly resistant to Vif-induced degradation even though the two proteins were found to interact in coimmunoprecipitation experiments and exhibited partial colocalization in transfected HeLa cells. Surprisingly, encapsidation and antiviral activity of APO3G C97A were both inhibited by Vif despite resistance to degradation. These results demonstrate that targeting of APO3G to proteasome degradation and interference with viral encapsidation are distinct functional properties of Vif.Keywords
This publication has 57 references indexed in Scilit:
- Antiviral Protein APOBEC3G Localizes to Ribonucleoprotein Complexes Found in P Bodies and Stress GranulesJournal of Virology, 2007
- Inhibition of \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\mathrm{tRNA}_{3}^{\mathrm{Lys}}\) \end{document}-Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency Virus Type 1 ReplicationJournal of Virology, 2006
- High-molecular-mass APOBEC3G complexes restrict Alu retrotranspositionProceedings of the National Academy of Sciences, 2006
- Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine DeaminationJournal of Virology, 2006
- Monomeric APOBEC3G Is Catalytically Active and Has Antiviral ActivityJournal of Virology, 2006
- Human Retroviral Host Restriction Factors APOBEC3G and APOBEC3F Localize to mRNA Processing BodiesPLoS Pathogens, 2006
- Genome-Wide Analysis of Group A Streptococci Reveals a Mutation That Modulates Global Phenotype and Disease SpecificityPLoS Pathogens, 2006
- HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particlesBiochemical and Biophysical Research Communications, 2004
- Functional domains of APOBEC3G required for antiviral activityJournal of Cellular Biochemistry, 2004
- Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcriptsNature, 2003